US price-fixing litigation targeting Teva has been selected as a priority for trial, making it a “bellwether” case, as part of the wider ongoing US investigation into generic price-fixing allegations.
The decision by a district court for the eastern district of Pennsylvania came shortly after a third major price-fixing lawsuit was filed in the US in June, focusing mainly on topical drugs. (Also see "Third Price-Fixing Lawsuit Filed In US" - Generics Bulletin, 11 June, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?